Skip to content
2000
image of Determinants of Early Atherosclerotic Changes in Adults with Growth Hormone Deficiency Receiving Replacement Therapy: A Cross-sectional Analysis of Intima-media Thickness and Endothelial Function

Abstract

Background

Patients with adult growth hormone deficiency (AGHD) show accelerated atherosclerosis. While growth hormone replacement therapy (GHRT) may help mitigate this process, the mechanisms driving atherosclerosis progression in GHRT-treated patients with AGHD remain unclear.

Methods

Thirty-one patients with AGHD on daily GHRT for ≥5 years were assessed in this cross-sectional study. Carotid intima-media thickness (cIMT) was evaluated by ultrasound. Reactive hyperemia index (RHI) was measured using peripheral arterial tonometry. Associations between vascular measures and clinical, pituitary, treatment, body composition, and laboratory parameters were evaluated.

Results

cIMT correlated with body mass index (r=0.584, p=0.001) and visceral adipose tissue area (r=0.791, p<0.001), while demonstrating nominally significant associations with triglyceride levels, insulin resistance index, smoking history, and arterial hypertension. Neither the current nor the 5-year mean insulin-like growth factor 1 standard deviation score directly correlated with vascular parameters. Median cIMT was higher in adult-onset compared with child-onset AGHD (0.70 . 0.58 mm; p=0.020), while median RHI was lower in genetic than structural etiology (1.58 . 2.18; p=0.010); however, both associations were nominally significant.

Discussion

Several of the identified cardiovascular risk factors associated with cIMT are unlikely to be sufficiently controlled through GHRT. Pituitary disease characteristics may play a role in atherogenesis; however, the subgroups defined by disease onset timing and etiology were small and not fully comparable.

Conclusion

In long-term GHRT-treated patients, cIMT is linked to well-established cardiovascular risk factors rather than features of the pituitary disorder and its management, highlighting the need for targeted cardiovascular risk management alongside GHRT in AGHD.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cvp/10.2174/0115701611413426251202060649
2026-01-16
2026-02-06

  • From This Site

    /content/journals/cvp/10.2174/0115701611413426251202060649
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. R H A J Dp M Growth hormone, atherosclerosis and peripheral arterial disease: Exploring the spectrum from acromegaly to growth hormone deficiency. Curr. Vasc. Pharmacol. 2024 22 1 28 35 10.2174/0115701611269162231106042956 37962050
    [Google Scholar]
  2. Colao A. The GH–IGF‐I axis and the cardiovascular system: Clinical implications. Clin. Endocrinol. 2008 69 3 347 358 10.1111/j.1365‑2265.2008.03292.x 18462260
    [Google Scholar]
  3. Gazzaruso C. Gola M. Karamouzis I. Giubbini R. Giustina A. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update. J. Clin. Endocrinol. Metab. 2014 99 1 18 29 10.1210/jc.2013‑2394 24217903
    [Google Scholar]
  4. Ratku B. Sebestyén V. Erdei A. Nagy E.V. Szabó Z. Somodi S. Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile. Pituitary 2022 25 2 211 228 10.1007/s11102‑022‑01207‑1 35106704
    [Google Scholar]
  5. Oglesby I.K. Slattery D. Glynn N. The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients. BMC Endocr. Disord. 2023 23 1 197 10.1186/s12902‑023‑01448‑6 37705005
    [Google Scholar]
  6. Di Somma C. Scarano E. Savastano S. Savanelli M.C. Pivonello R. Colao A. Cardiovascular alterations in adult GH deficiency. Best Pract. Res. Clin. Endocrinol. Metab. 2017 31 1 25 34 10.1016/j.beem.2017.03.005 28477729
    [Google Scholar]
  7. Pfeifer M. Verhovec R. Zizek B. Prezelj J. Poredos P. Clayton R.N. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. 1999 84 2 453 457 10.1210/jc.84.2.453 10022400
    [Google Scholar]
  8. Abdu T.A.M. Elhadd T.A. Buch H. Barton D. Neary R. Clayton R.N. Recombinant GH replacement in hypopituitary adults improves endothelial cell function and reduces calculated absolute and relative coronary risk. Clin. Endocrinol. 2004 61 3 387 393 10.1111/j.1365‑2265.2004.02109.x 15355457
    [Google Scholar]
  9. Tsukahara H. Gordienko D.V. Tonshoff B. Gelato M.C. Goligorsky M.S. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994 45 2 598 604 10.1038/ki.1994.78 7513035
    [Google Scholar]
  10. McCallum R.W. Sainsbury C.A.R. Spiers A. Growth hormone replacement reduces C‐reactive protein and large‐artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clin. Endocrinol. 2005 62 4 473 479 10.1111/j.1365‑2265.2005.02245.x 15807879
    [Google Scholar]
  11. Colao A. Di Somma C. Filippella M. Insulin‐like growth factor‐1 deficiency determines increased intima–media thickness at common carotid arteries in adult patients with growth hormone deficiency. Clin. Endocrinol. 2004 61 3 360 366 10.1111/j.1365‑2265.2004.02105.x 15355453
    [Google Scholar]
  12. Deanfield J.E. Halcox J.P. Rabelink T.J. Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007 115 10 1285 1295 10.1161/CIRCULATIONAHA.106.652859 17353456
    [Google Scholar]
  13. Libby P. Ridker P.M. Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011 473 7347 317 325 10.1038/nature10146 21593864
    [Google Scholar]
  14. Colao A. Di Somma C. Spiezia S. Growth hormone treatment on atherosclerosis: Results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J. Clin. Endocrinol. Metab. 2008 93 9 3416 3424 10.1210/jc.2007‑2810 18593773
    [Google Scholar]
  15. Höybye C. Biller B.M.K. Ferran J-M. Reduced CV risk with long-term GH replacement in AGHD: Data from two large observational studies. Endocr. Connect. 2022 12 1 220267 36347049
    [Google Scholar]
  16. van Bunderen C.C. Olsson D.S. Meta-analysis of mortality in adults with growth hormone deficiency: Does growth hormone replacement therapy really improve mortality rates? Best Pract. Res. Clin. Endocrinol. Metab. 2023 37 6 101835 10.1016/j.beem.2023.101835 37914564
    [Google Scholar]
  17. Molitch M.E. Clemmons D.R. Malozowski S. Merriam G.R. Vance M.L. Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011 96 6 1587 1609 10.1210/jc.2011‑0179 21602453
    [Google Scholar]
  18. Ho K.K. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: A statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur. J. Endocrinol. 2007 157 6 695 700 10.1530/EJE‑07‑0631 18057375
    [Google Scholar]
  19. Vijayakumar A. Yakar S. LeRoith D. The intricate role of growth hormone in metabolism. Front. Endocrinol. 2011 2 32 10.3389/fendo.2011.00032 22654802
    [Google Scholar]
  20. Agha A. Monson J.P. Modulation of glucocorticoid metabolism by the growth hormone – IGF‐1 axis. Clin. Endocrinol. 2007 66 4 459 465 10.1111/j.1365‑2265.2007.02763.x 17371460
    [Google Scholar]
  21. Aparecida Silveira E. Vaseghi G. de Carvalho Santos A.S. Visceral obesity and its shared role in cancer and cardiovascular disease: A scoping review of the pathophysiology and pharmacological treatments. Int. J. Mol. Sci. 2020 21 23 9042 10.3390/ijms21239042 33261185
    [Google Scholar]
  22. Ukropec J. Penesová A. Škopková M. Adipokine protein expression pattern in growth hormone deficiency predisposes to the increased fat cell size and the whole body metabolic derangements. J. Clin. Endocrinol. Metab. 2008 93 6 2255 2262 10.1210/jc.2007‑2188 18334583
    [Google Scholar]
  23. Cenci M.C.P. Soares D.V. Spina L.D.C. Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency. Pituitary 2009 12 4 322 329 10.1007/s11102‑009‑0182‑2 19390974
    [Google Scholar]
  24. Spina L.D.C. Soares D.V. Brasil R.R.L.O. Glucose metabolism and visceral fat in GH deficient adults: 1 year of GH replacement. Growth Horm. IGF Res. 2004 14 1 45 51 10.1016/j.ghir.2003.08.002 14700554
    [Google Scholar]
  25. Beauregard C. Utz A.L. Schaub A.E. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: A randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 2008 93 6 2063 2071 10.1210/jc.2007‑2371 18381581
    [Google Scholar]
  26. Colao A. Di Somma C. Rota F. Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J. Clin. Endocrinol. Metab. 2005 90 4 2056 2062 10.1210/jc.2004‑2247 15671089
    [Google Scholar]
  27. Borson-Chazot F. Serusclat A. Kalfallah Y. Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J. Clin. Endocrinol. Metab. 1999 84 4 1329 1333 10.1210/jc.84.4.1329 10199774
    [Google Scholar]
  28. Colao A. Di Somma C. Cuocolo A. Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency. J. Clin. Endocrinol. Metab. 2005 90 9 5146 5155 10.1210/jc.2005‑0597 15985481
    [Google Scholar]
  29. Cenci M.C.P. Conceição F.L. Soares D.V. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone–deficient adults. Metabolism 2008 57 1 121 129 10.1016/j.metabol.2007.08.015 18078869
    [Google Scholar]
  30. Soares D.V. Spina L.D.C. de Lima Oliveira Brasil R.R. Carotid artery intima-media thickness and lipid profile in adults with growth hormone deficiency after long-term growth hormone replacement. Metabolism 2005 54 3 321 329 10.1016/j.metabol.2004.09.011 15736109
    [Google Scholar]
  31. Biscotto I.P. Costa Hong V.A. Batista R.L. Vasculometabolic effects in patients with congenital growth hormone deficiency with and without GH replacement therapy during adulthood. Pituitary 2021 24 2 216 228 10.1007/s11102‑020‑01099‑z 33098037
    [Google Scholar]
  32. Gómez J.M. Sahún M. Vila R. Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with growth hormone deficiency. Clin. Endocrinol. 2006 64 6 632 639 10.1111/j.1365‑2265.2006.02518.x 16712664
    [Google Scholar]
  33. Attanasio A.F. Lamberts S.W. Matranga A.M. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J. Clin. Endocrinol. Metab. 1997 82 1 82 88 10.1210/jc.82.1.82 8989238
    [Google Scholar]
  34. Yang H. Xu H. Wang L. Metabolic profile and echocardiographic evaluation in adults with growth hormone deficiency. Horm. Metab. Res. 2022 54 12 827 832 10.1055/a‑1941‑8556 36257327
    [Google Scholar]
  35. Murata M. Kaji H. Mizuno I. A study of carotid intima-media thickness in GH-deficient Japanese adults during onset among adults and children. Eur. J. Endocrinol. 2003 148 3 333 338 10.1530/eje.0.1480333 12611614
    [Google Scholar]
  36. Hepprich M. Ebrahimi F. Christ E. Dyslipidaemia and growth hormone deficiency – A comprehensive review. Best Pract. Res. Clin. Endocrinol. Metab. 2023 37 6 101821 10.1016/j.beem.2023.101821 37821339
    [Google Scholar]
  37. Maison P. Griffin S. Nicoue-Beglah M. Haddad N. Balkau B. Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: A metaanalysis of blinded, randomized, placebo-controlled trials. J. Clin. Endocrinol. Metab. 2004 89 5 2192 2199 10.1210/jc.2003‑030840 15126541
    [Google Scholar]
  38. Elbornsson M. Götherström G. Bosæus I. Bengtsson B.Å. Johannsson G. Svensson J. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur. J. Endocrinol. 2013 168 5 745 753 10.1530/EJE‑12‑1083 23428613
    [Google Scholar]
  39. Zhang S. Li Z. Lv Y. Cardiovascular effects of growth hormone (GH) treatment on GH-deficient adults: A meta-analysis update. Pituitary 2020 23 4 467 475 10.1007/s11102‑020‑01036‑0 32166618
    [Google Scholar]
  40. Sverrisdóttir Y.B. Elam M. Caidahl K. Söderling A-S. Herlitz H. Johannsson G. The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: A double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults. J. Hypertens. 2003 21 10 1905 1914 10.1097/00004872‑200310000‑00018 14508197
    [Google Scholar]
  41. Böger R.H. Skamira C. Bode-Böger S.M. Brabant G. von zur Muhlen A. Frolich J.C. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J. Clin. Invest. 1996 98 12 2706 2713 10.1172/JCI119095 8981915
    [Google Scholar]
  42. de Gregorio C. Andò G. Cannavò S. Cardiovascular outcomes and conventional risk factors in non-diabetic adult patients with GH deficiency: A long-term retrospective cohort study. Eur. J. Intern. Med. 2015 26 10 813 818 10.1016/j.ejim.2015.10.017 26548714
    [Google Scholar]
  43. Garmes H.M. Special features on insulin resistance, metabolic syndrome and vascular complications in hypopituitary patients. Rev. Endocr. Metab. Disord. 2024 25 3 489 504 10.1007/s11154‑023‑09872‑8 38270844
    [Google Scholar]
  44. Roemmler J. Kuenkler M. Schneider H.J. Dieterle C. Schopohl J. Comparison of glucose and lipid metabolism and bone mineralization in patients with growth hormone deficiency with and without long-term growth hormone replacement. Metabolism 2010 59 3 350 358 10.1016/j.metabol.2009.08.002 19800640
    [Google Scholar]
  45. Seki Y. Morimoto S. Bokuda K. Effect of GH deficiency caused by nonfunctioning pituitary masses on serum c-reactive protein levels. J. Endocr. Soc. 2023 7 12 bvad137 10.1210/jendso/bvad137 38024646
    [Google Scholar]
  46. Ajoolabady A. Pratico D. Lin L. Inflammation in atherosclerosis: Pathophysiology and mechanisms. Cell Death Dis. 2024 15 11 817 10.1038/s41419‑024‑07166‑8 39528464
    [Google Scholar]
  47. Hayes F.J. Fiad T.M. McKenna T.J. Gender difference in the response of growth hormone (GH)-deficient adults to GH therapy. Metabolism 1999 48 3 308 313 10.1016/S0026‑0495(99)90077‑X 10094105
    [Google Scholar]
  48. Slagboom T.N.A. van der Lely A.J. Drent M.L. van Bunderen C.C. Exploring the sex difference in cardiovascular risk during growth hormone therapy in adults. Eur. J. Endocrinol. 2024 190 6 434 445 10.1093/ejendo/lvae060 38798228
    [Google Scholar]
  49. Burman P. Johansson A.G. Siegbahn A. Vessby B. Karlsson F.A. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J. Clin. Endocrinol. Metab. 1997 82 2 550 555 10.1210/jc.82.2.550 9024252
    [Google Scholar]
  50. Höybye C. Weber M.M. Pournara E. Tønnes Pedersen B. Biller B.M.K. Is GH dosing optimal in female patients with adult‐onset GH deficiency? An analysis from the NordiNet ® International Outcome Study. Clin. Endocrinol. 2017 86 6 798 805 10.1111/cen.13330 28306165
    [Google Scholar]
  51. Klinc A. Janež A. Jensterle M. Long-term IGF-1 maintenance in the upper-normal range has beneficial effect on low-grade inflammation marker in adults with growth hormone deficiency. Int. J. Mol. Sci. 2025 26 5 2010 10.3390/ijms26052010 40076636
    [Google Scholar]
  52. Schneider H.J. Klotsche J. Wittchen H.U. Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin. Endocrinol. 2011 75 6 825 830 10.1111/j.1365‑2265.2011.04137.x 21658091
    [Google Scholar]
  53. Capaldo B. Guardasole V. Pardo F. Abnormal vascular reactivity in growth hormone deficiency. Circulation 2001 103 4 520 524 10.1161/01.CIR.103.4.520 11157716
    [Google Scholar]
  54. Evans L.M. Davies J.S. Anderson R.A. The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur. J. Endocrinol. 2000 142 3 254 262 10.1530/eje.0.1420254 10700719
    [Google Scholar]
  55. Smith J.C. Evans L.M. Wilkinson I. Effects of GH replacement on endothelial function and large‐artery stiffness in GH‐deficient adults: A randomized, double‐blind, placebo‐controlled study. Clin. Endocrinol. 2002 56 4 493 501 10.1046/j.1365‑2265.2002.01514.x 11966742
    [Google Scholar]
  56. Suzuki K. Yanagi K. Shimizu M. Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study. Endocr. J. 2018 65 1 101 111 10.1507/endocrj.EJ17‑0330 29070768
    [Google Scholar]
  57. Borson-Chazot F. Chabre O. Salenave S. Adherence to growth hormone therapy guidelines in a real-world French cohort of adult patients with growth hormone deficiency. Ann. Endocrinol. 2021 82 1 59 68 10.1016/j.ando.2020.11.007 33290752
    [Google Scholar]
  58. Ebrahimi F. Christ E. Why do patients with hypopituitarism still present an increased mortality? Ann. Endocrinol. 2023 84 2 285 290 10.1016/j.ando.2023.02.002 36809815
    [Google Scholar]
/content/journals/cvp/10.2174/0115701611413426251202060649
Loading
Determinants of Early Atherosclerotic Changes in Adults with Growth Hormone Deficiency Receiving Replacement Therapy: A Cross-sectional Analysis of Intima-media Thickness and Endothelial Function
Bentham Science Publishers ; https://doi.org/10.2174/0115701611413426251202060649
/content/journals/cvp/10.2174/0115701611413426251202060649
/content/journals/cvp/10.2174/0115701611413426251202060649
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: growth hormone replacement therapy ; cardiovascular risk ; reactive hyperemia index ; Adult growth hormone deficiency ; intima-media thickness ; endothelial function ; visceral adipose tissue

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test